Weak Guidance Leads to Hologic Downgrade | GenomeWeb

NEW YORK (GenomeWeb News) – Following Hologic's announcement that its Fiscal Year 2014 revenues will be down year over year, investment firm William Blair today downgraded the firm's stock to Market Perform from a previous rating of Outperform.

Analyst Brian Weinstein also reduced his revenue and earnings estimates for Hologic for FY 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.